JP6884792B2 - がん及び新生物の治療方法及び治療用組成物 - Google Patents

がん及び新生物の治療方法及び治療用組成物 Download PDF

Info

Publication number
JP6884792B2
JP6884792B2 JP2018543712A JP2018543712A JP6884792B2 JP 6884792 B2 JP6884792 B2 JP 6884792B2 JP 2018543712 A JP2018543712 A JP 2018543712A JP 2018543712 A JP2018543712 A JP 2018543712A JP 6884792 B2 JP6884792 B2 JP 6884792B2
Authority
JP
Japan
Prior art keywords
cells
asc
cancer
cell
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018543712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509999A5 (https=
JP2019509999A (ja
Inventor
ザミ アバーマン、
ザミ アバーマン、
オフィル、レイチェル
イッサチャー アレン、ホシア
イッサチャー アレン、ホシア
ジレート、アリエル
ヘレド、ニヴァ シュラガ
ヘレド、ニヴァ シュラガ
Original Assignee
プルリステム リミテッド
プルリステム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プルリステム リミテッド, プルリステム リミテッド filed Critical プルリステム リミテッド
Publication of JP2019509999A publication Critical patent/JP2019509999A/ja
Publication of JP2019509999A5 publication Critical patent/JP2019509999A5/ja
Application granted granted Critical
Publication of JP6884792B2 publication Critical patent/JP6884792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018543712A 2016-02-18 2017-02-16 がん及び新生物の治療方法及び治療用組成物 Expired - Fee Related JP6884792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296621P 2016-02-18 2016-02-18
US62/296,621 2016-02-18
PCT/IB2017/050868 WO2017141181A1 (en) 2016-02-18 2017-02-16 Methods and compositions for treating cancers and neoplasms

Publications (3)

Publication Number Publication Date
JP2019509999A JP2019509999A (ja) 2019-04-11
JP2019509999A5 JP2019509999A5 (https=) 2020-03-26
JP6884792B2 true JP6884792B2 (ja) 2021-06-09

Family

ID=58266008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018543712A Expired - Fee Related JP6884792B2 (ja) 2016-02-18 2017-02-16 がん及び新生物の治療方法及び治療用組成物

Country Status (7)

Country Link
US (1) US20210205370A1 (https=)
EP (1) EP3416662B1 (https=)
JP (1) JP6884792B2 (https=)
AU (1) AU2017220148A1 (https=)
CA (1) CA3012741A1 (https=)
IL (1) IL261146B (https=)
WO (1) WO2017141181A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20210000882A1 (en) * 2018-02-28 2021-01-07 Crown Scientific, LLC Production and use of extracellular vesicles
US20210115395A1 (en) * 2018-03-28 2021-04-22 Pluristem Ltd. Methods for expanding adherent stromal cells and cells obtained thereby
JP7538044B2 (ja) * 2018-04-30 2024-08-21 ザ チルドレンズ メディカル センター コーポレーション 間葉系間質細胞エキソソームおよびそれらの使用
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
AU2019359890B2 (en) * 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20220323412A1 (en) * 2019-09-06 2022-10-13 Chi-Chih Kang Extracellular vesicle-fenretinide compositions, extracellular vesicle-c-kit inhibitor compositions, methods of making and uses thereof
WO2022059026A1 (en) * 2020-09-21 2022-03-24 Mestastop Solutions Private Limited Systems and methods for predicting cancer metastasis and screening of drugs
JP7849911B2 (ja) * 2021-09-27 2026-04-22 金湧長生醫學生物科技股▲ふん▼有限公司 脱落膜胎盤間葉系幹細胞及び血管新生促進医薬組成物の製造におけるその用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
JPS6410979A (en) 1987-07-03 1989-01-13 Mitsubishi Chem Ind Microcarrier for cultivating cell
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
DE69903800T2 (de) 1998-03-18 2003-10-02 Massachusetts Institute Of Technology, Cambridge Vaskularisierte perfundierte anordnungen für mikrogewebe und mikroorgane
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
EP1261694B1 (en) 2000-02-26 2008-01-16 Artecel, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
EP2366775B1 (en) 2006-03-23 2015-04-22 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US7531334B2 (en) 2006-04-14 2009-05-12 Xerox Corporation Polymeric microcarriers for cell culture functions
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
MX2010003019A (es) * 2007-09-19 2010-04-30 Pluristem Ltd Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
NZ599825A (en) * 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8828720B2 (en) 2008-03-17 2014-09-09 Agency For Science, Technology And Research Microcarriers for stem cell culture
CN105708862B (zh) * 2008-09-02 2020-11-06 普拉里斯坦有限公司 来自胎盘组织的粘附细胞及其在治疗中的用途
EP3150703A1 (en) 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
EP2977445B1 (en) 2009-11-30 2018-07-25 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
DK3284818T3 (da) * 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
EP2561066B1 (en) * 2010-04-23 2016-03-30 Pluristem Ltd. Adherent stromal cells derived from plancentas of multiple donors and uses thereof
CN103476924A (zh) 2011-04-15 2013-12-25 普拉里斯坦有限公司 收获细胞的方法和系统
RU2615179C2 (ru) 2012-09-06 2017-04-04 Плуристем Лтд. Устройства и способы культивирования клеток
WO2014066122A1 (en) * 2012-10-24 2014-05-01 The Texas A&M University System Treatment of tumors with activated mesenchymal stem cells
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
US20180015125A1 (en) 2015-03-23 2018-01-18 Pluristem Ltd. Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof

Also Published As

Publication number Publication date
EP3416662B1 (en) 2020-07-29
CA3012741A1 (en) 2017-08-24
WO2017141181A1 (en) 2017-08-24
EP3416662A1 (en) 2018-12-26
IL261146B (en) 2022-07-01
US20210205370A1 (en) 2021-07-08
AU2017220148A1 (en) 2018-07-19
IL261146A (en) 2018-10-31
JP2019509999A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
JP6884792B2 (ja) がん及び新生物の治療方法及び治療用組成物
Raynaud et al. Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation
Noll et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells
US10722541B2 (en) Methods for treating radiation or chemical injury
Gamwell et al. The mouse ovarian surface epithelium contains a population of LY6A (SCA-1) expressing progenitor cells that are regulated by ovulation-associated factors
US20110171182A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
JP6382408B2 (ja) 体性幹細胞
US20230126485A1 (en) Pancreatic stem cells and uses thereof
Ordonez et al. Human limbal epithelial progenitor cells express αvβ5-integrin and the interferon-inducible chemokine CXCL10/IP-10
JP2023026662A (ja) 血管形成の調節
WO2011062584A1 (en) Reducing inflammation using cell therapy
JP2016540770A (ja) 新生物の処置方法
Nitta et al. Conversion of mesenchymal stem cells into a canine hepatocyte-like cells by Foxa1 and Hnf4a
IL268268A (en) Methods and compounds for the evaluation of cancerous tumors
CN103540566A (zh) 用于长期造血种群恢复的方法和组合物
Manohar et al. Identification and expansion of a unique stem cell population from adult mouse gallbladder
KR102011634B1 (ko) 향상된 산후 부착형 세포 및 그의 용도
WO2020095230A1 (en) Therapeutic methods and compositions
Brown Investigating the effects of mesenchymal stem cells and exercise on breast cancer progression in vitro
KR20250145615A (ko) 효력 검정 및 제조 방법
US20150157663A1 (en) Pharmaceutical Composition Comprising Human-Blood-Derived-Cell Mass
WO2011162623A1 (en) Stem cell population and methods of isolation and use thereof
AU2016256806A1 (en) Modulation of angiogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200214

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200408

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210512

R150 Certificate of patent or registration of utility model

Ref document number: 6884792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees